Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor Antagonist in Patients with Schizophrenia and Hyponatremia

Biological Psychiatry

Volumn 64, Issue 12, 2008, Pages 1097-1100

  Josiassen, Richard C ^a,b   Goldman, Morris ^d   Jessani, Meera ^a   Shaughnessy, Rita A ^a,c   Albazzaz, Ala ^d   Lee, Jennifer ^e   Ouyang, John ^e   Orlandi, Cesare ^e   Czerwiec, Frank ^e  

^a Arthur P Noyes Research Foundation Norristown   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Otsuka Pharmaceutical Development and Commercialization   (United States)

Author keywords

Hyponatremia; schizophrenia; tolvaptan; vasopressin V2 receptor antagonist

Indexed keywords

CHLORPROMAZINE; PLACEBO; SODIUM CHANNEL; TOLVAPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ATAXIA; CENTRAL PONTINE MYELINOLYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLUID INTAKE; HUMAN; HYPONATREMIA; HYPOTENSION; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SLURRED SPEECH; SODIUM BLOOD LEVEL; TREATMENT DURATION;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; SCHIZOPHRENIA; TIME FACTORS;

EID: 56349152555     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.06.017     Document Type: Article

References (20)

1. Hoskins R.G. Schizophrenia from the physiological point of view. Ann Intern Med 7 (1933) 445-456
2. Targowla R. Des troubles fonctionnel du rein dans les maladies mentales. L'excretion del'eau (Kidney malfunction and mental illness: Water excretion. Bull Soc Med Hop Paris 47 (1923) 1711-1715
3. Barahal H.S. Water intoxication in a mental case. Psychiat Quart 12 (1938) 767-771
4. Vieweg W.V., David J.J., Rowe W.T., Wampler G.J., Burns W.J., and Spradlin W.W. Death from self-induced water intoxication among patients with schizophrenic disorders. J Nerv Ment Dis 173 (1988) 161-165
5. de Leon J., Verghese C., Tracy J.I., Josiassen R.C., and Simpson G.M. Polydipsia and water intoxication in psychiatric patients: A review of the epidemiological literature. Biol Psychiatry 35 (1994) 519-530
6. Shutty Jr. M.S., Briscoe L., Sautter S., and Leadbetter R.A. Neuropsychological manifestations of hyponatremia in chronic schizophrenia patients with the syndrome of psychosis, intermittent hyponatremia and polydipsia (PIP). Schizophr Res 10 (1993) 125-130
7. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol 59 (2006) 229-236
8. Renneboog B., Musch W., Vandemergel X., Manto M.U., and Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 119 (2006) 71
9. Delva N.J., Crammer J.L., Jarzylo S.V., Lawson J.S., Owen J.A., Sribney M., et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry 26 (1989) 781-793
10. Vieweg W.V. Treatment strategies in the polydipsia-hyponatremia syndrome. J Clin Psychiatry 55 (1994) 154-160
11. Canuso C.M., and Goldman M.B. Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. J Neuropsychiatry Clin Neurosci 11 (1999) 86-90
12. Wong L.L., and Verbalis J.G. Vasopressin V2 receptor antagonists. Cardiovasc Res 51 (2001) 391-402
13. Udelson J.E., Smith W.B., Hendrix G.H., Painchaud C.A., Ghazzi M., Thomas I., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (2001) 2417-2423
14. Saito T., Ishikawa S., Abe K., Kamoi K., Yamada K., Shimizu K., et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocr Metab 82 (1997) 1054-1057
15. Yamamura Y., Nakamura S., Itoh S., Hirano T., Onogawa T., Yamashita T., et al. OPC-41061, a highly potent vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287 (1998) 860-867
16. Hirano T., Yamamura Y., Nakamura S., Onogawa T., and Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 292 (2000) 288-294
17. Costello-Boerrigter L.C., Smith W.B., Boerringter G., Ouyang J., Zimmer C.A., Orlandi C., et al. Vasopressin 2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol-Renal 290 (2006) F273-F278
18. 2-receptor antagonist, for hyponatremia. N Engl J Med 355 (2006) 2099-2112
19. Weise W.J., Rimmer J.M., and Hood V.L. Tolvaptan for hyponatremia. N Engl J Med 356 (2007) 961
20. Alvelos M., Ferreira A., Bettencourt P., Pimenta J., Azevedo A., Serrão P., et al. Effect of saline load and metoclopramide on the renal dopaminergic system in patients with heart failure and healthy controls. J Cardiovasc Pharm 45 (2005) 197-203